特发性肺纤维化患者血清透明质酸、层粘连蛋白的变化及意义

摘要
图/表
参考文献(20)
相关文章 (5)

全文: PDF (492 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨特发性肺纤维化（IPF）患者血清透明质酸（HA）、层粘连蛋白（LN）的变化及意义。方法选择2014年6月～2016年6月在杭州师范大学附属医院呼吸科诊治的IPF患者38例为IPF组，选择同期健康非吸烟者30例为对照组。采用放射免疫法检测IPF患者及对照组血清HA、LN的水平；并与肺功能、6 min步行试验（6MWT）、呼吸困难评分等指标进行相关分析。结果与对照组比较，IPF组患者血清HA、LN水平显著升高（P < 0.05）。IPF患者血清HA、LN水平分别与用力肺活量（FVC）、第1秒用力呼气量（FEV1）、一氧化碳弥散量（DLCO）呈负相关（均r < 0，P < 0.05或P < 0.01）；HA、LN水平与6MWT呈负相关（r = -0.637、-0.705，P < 0.01），与mMRC评分呈正相关（r = 0.618、0.552，P < 0.05）。结论血清HA、LN水平可作为评价IPF病情严重程度、判断疗效的指标，值得在临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈学远李雅倩冯哲敏何文波孙一波

关键词 ：特发性肺纤维化, 透明质酸, 层粘连蛋白

Abstract：Objective To explore the level and significance of serum hyaluronic acid (HA) and laminin (LN) in patients with idiopathic pulmonary fibrosis (IPF). Methods From June 2014 to June 2016 , in Department of Respiratory Diseases, Affiliated Hospital of Hangzhou Normal University, 38 patients with IPF were selected as control group, and 30 healthy persons without smoking at same time were selected as control group. The levels of serum HA and LN in IPF patients and cotrol group were detected by radioimmunoassay. And the correlation between serum HA, LN with lung function, 6-minute walk test (6MWT) and dyspnea score was evaluated. Results Compared with the control group, the levels of serum HA and LN of patients in IPF group were significantly higher (P < 0.05). The levels of serum HA and LN in patients with IPF were negatively correlated with FVC, FEV1 and DLCO (all r < 0, P < 0.05 or P < 0.01); HA and LN were negatively correlated with 6MWT (r = -0.637, -0.705, P < 0.01); the levels of serum HA and LN in IPF patients were positively correlated with mMRC score (r = 0.618, 0.552, P < 0.05). Conclusion These data suggest that serum HA and LN may be useful biomarkers to estimate the severity and treatment effect of patients with IPF.

Key words： Idiopathic pulmonary fibrosis Hyaluronic acid Laminin

基金资助:浙江省中医药科学研究基金项目（2016ZB101）；
浙江省医药卫生科技计划项目（2017KY525）；
浙江省杭州市社会发展自主申报项目（医疗卫生领域）（20160533B20）；
杭州师范大学附属医院国家级项目预研基金项目。

作者简介: 陈学远（1971.4-），男，博士，副主任医师，硕士研究生导师；研究方向：间质性肺疾病。

引用本文:

陈学远李雅倩冯哲敏何文波孙一波. 特发性肺纤维化患者血清透明质酸、层粘连蛋白的变化及意义[J]. 中国医药导报, 2017, 14(16): 44-46.
CHEN Xueyuan LI Yaqian FENG Zhemin HE Wenbo SUN Yibo. Level and significance of serum hyaluronic acid and laminin in patients with idiopathic pulmonary fibrosis. 中国医药导报, 2017, 14(16): 44-46.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2017/V14/I16/44

[1] Travis WD，Costabel U，Hansell DM，et al. An official American Thoracic Society/European Respiratory Society statement：Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med，2013，188（6）：733-748.
[2] King TE Jr，Pardo A，Selman M. Idiopathic pulmonary fibrosis [J]. Lancet，2011，378（9807）：1949-1961.
[3] Sgalla G，Biffi A，Richeldi L. Idiopathic pulmonary fibrosis：Diagnosis，epidemiology and natural history [J]. Respirology，2016，21（3）：427-437.
[4] Raghu G，Collard HR，Egan JJ，et al. An official ATS/ERS/JRS/ALAT statement：idiopathic pulmonary fibrosis：evidence-based guidelines for diagnosis and management [J]. Am J Respir Crit Care Med，2011，183（6）：788-824.
[5] Raghu G，Rochwerg B，Zhang Y，et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline：Treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline [J]. Am J Respir Crit Care Med，2015， 192（2）：e3-e19.
[6] King TE Jr，Tooze JA，Schwarz MI，et al. Predicting survival in idiopathic pulmonary fibrosis：scoring system and survival model [J]. Am J Respir Crit Care Med，2001，164（7）：1171-1181.
[7] Ohshimo S，Yokoyama A，Hattori N，et al. KL-6，a human MUC1 mucin，promotes proliferation and survival of lung fibroblasts [J]. Biochem Biophys Res Commun，2005，338（4）：1845-1852.
[8] Ohshimo S，Ishikawa N，Horimasu Y，et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis [J]. Respir Med，2014，108（7）：1031-1039.
[9] Greene KE，King TE Jr，Kuroki Y，et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis [J]. Eur Respir J，2002，19（3）：439-446.
[10] Kinder BW，Brown KK，McCormack FX，et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis [J]. Chest ，2009，135（6）：1557-1563.
[11] Prasse A，Probst C，Bargagli E，et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis [J]. Am J Respir Crit Care Med，2009， 179（8）：717-723.
[12] Cai M，Bonella F，He X，et al. CCL18 in serum，BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases [J]. Respir Med，2013，107（9）：1444-1452.
[13] DePianto DJ，Chandriani S，Abbas AR，et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis [J]. Thorax，2015，70（1）：48-56.
[14] Prasse A，Müller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis [J]. Respirology，2009，14（6）：788-795.
[15] Zhang Y，Kaminski N. Biomarkers in idiopathic pulmonary fibrosis [J]. Curr Opin Pulm Med，2012，18（5）：441-446.
[16] Song JW，Do KH，Jang SJ，et al. Blood biomarkers MMP-7 and SP-A：predictors of outcome in idiopathic pulmonary fibrosis [J]. Chest，2013，143（5）：1422-1429.
[17] Guiot J，Henket M，Corhay JL，et al. Sputum biomarkers in IPF：Evidence for raised gene expression and protein level of IGFBP-2，IL-8 and MMP-7 [J]. PLoS One，2017， 12（2）：e0171344.
[18] White ES，Xia M，Murray S，et al. Plasma surfactant protein-d，matrix metalloproteinase-7，and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias [J]. Am J Respir Crit Care Med，2016，194（10）：1242-1251.
[19] Inokoshi Y，Tanino Y，Wang X，et al. Clnical Significance of Serum Hyaluronan in Chronic Fibrotic Interstitial Pneumonia [J]. Respirology，2013，18 （8）：1236-1243.
[20] Lappi-Blanco E，Kaarteenaho-Wiik R，Salo S，et al. Laminin-5 gamma 2 chain in cryptogenic organizing pneumonia and idiopathic pulmonary fibrosis [J]. Am J Respir Crit Care Med，2004，169（1）：27-33.